Catalent Stockholders Approve Transaction with Novo Holdings

Catalent stockholders approve deal with Novo Holdings

Catalent Stockholders Approve Transaction with Novo Holdings

Novo Nordisk owner buys majority stake in Austrian life science tools company

Catalent's (CTLT) Latest Partnership to Boost Clinical Trials

Catalent's (CTLT) Latest Partnership to Boost Clinical Trials

Ozempic Maker Novo Nordisk Plans Bond Sale to Fund Expansion

Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up

Lazard hires veteran healthcare dealmaker Colocci as vice chairman

Decoding Catalent Inc (CTLT): A Strategic SWOT Insight

Decoding Catalent Inc (CTLT): A Strategic SWOT Insight

Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates

Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates

Catalent, Inc. Reports Third Quarter Fiscal 2024 Results

FTC Seeks More Information on $16.5 Billion Novo-Catalent Deal

US FTC seeks more information on Novo Nordisk parent-Catalent deal

UPDATE 2-US FTC seeks more information on Novo Nordisk parent-Catalent deal

How Novo-Catalent Deal Affects Halozyme (HALO)?

Here’s How Novo Holdings’ Catalent (CTLT) Acquisition Affects Laughing Water Capital

Why Weight-Loss Drugs Wegovy, Zepbound Are in Short Supply